QQQ   416.98 (-1.52%)
AAPL   165.14 (-1.14%)
MSFT   399.25 (-1.24%)
META   484.04 (-3.54%)
GOOGL   153.51 (-1.60%)
AMZN   174.66 (-2.54%)
TSLA   148.73 (-0.80%)
NVDA   810.37 (-4.29%)
AMD   148.41 (-4.30%)
NIO   3.84 (-4.00%)
BABA   68.67 (-0.30%)
T   16.39 (+0.37%)
F   12.12 (+0.50%)
MU   107.68 (-3.80%)
GE   149.08 (-2.52%)
CGC   8.13 (+3.83%)
DIS   112.03 (-0.36%)
AMC   3.29 (+12.67%)
PFE   25.81 (+1.65%)
PYPL   62.14 (+0.06%)
XOM   120.16 (+1.38%)
QQQ   416.98 (-1.52%)
AAPL   165.14 (-1.14%)
MSFT   399.25 (-1.24%)
META   484.04 (-3.54%)
GOOGL   153.51 (-1.60%)
AMZN   174.66 (-2.54%)
TSLA   148.73 (-0.80%)
NVDA   810.37 (-4.29%)
AMD   148.41 (-4.30%)
NIO   3.84 (-4.00%)
BABA   68.67 (-0.30%)
T   16.39 (+0.37%)
F   12.12 (+0.50%)
MU   107.68 (-3.80%)
GE   149.08 (-2.52%)
CGC   8.13 (+3.83%)
DIS   112.03 (-0.36%)
AMC   3.29 (+12.67%)
PFE   25.81 (+1.65%)
PYPL   62.14 (+0.06%)
XOM   120.16 (+1.38%)
QQQ   416.98 (-1.52%)
AAPL   165.14 (-1.14%)
MSFT   399.25 (-1.24%)
META   484.04 (-3.54%)
GOOGL   153.51 (-1.60%)
AMZN   174.66 (-2.54%)
TSLA   148.73 (-0.80%)
NVDA   810.37 (-4.29%)
AMD   148.41 (-4.30%)
NIO   3.84 (-4.00%)
BABA   68.67 (-0.30%)
T   16.39 (+0.37%)
F   12.12 (+0.50%)
MU   107.68 (-3.80%)
GE   149.08 (-2.52%)
CGC   8.13 (+3.83%)
DIS   112.03 (-0.36%)
AMC   3.29 (+12.67%)
PFE   25.81 (+1.65%)
PYPL   62.14 (+0.06%)
XOM   120.16 (+1.38%)
QQQ   416.98 (-1.52%)
AAPL   165.14 (-1.14%)
MSFT   399.25 (-1.24%)
META   484.04 (-3.54%)
GOOGL   153.51 (-1.60%)
AMZN   174.66 (-2.54%)
TSLA   148.73 (-0.80%)
NVDA   810.37 (-4.29%)
AMD   148.41 (-4.30%)
NIO   3.84 (-4.00%)
BABA   68.67 (-0.30%)
T   16.39 (+0.37%)
F   12.12 (+0.50%)
MU   107.68 (-3.80%)
GE   149.08 (-2.52%)
CGC   8.13 (+3.83%)
DIS   112.03 (-0.36%)
AMC   3.29 (+12.67%)
PFE   25.81 (+1.65%)
PYPL   62.14 (+0.06%)
XOM   120.16 (+1.38%)
Free Trial

Taysha Gene Therapies (TSHA) Earnings Date, Estimates & Call Transcripts

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)
Free TSHA Stock Alerts
$2.26
-0.15 (-6.22%)
(As of 12:51 PM ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media

Earnings Summary

Upcoming
Earnings Date
May. 9Estimated
Actual EPS
(Mar. 19)
$0.35 Beat By $0.35
Skip Charts & View Estimated and Actual Earnings Data
Earnings Per ShareRevenue

TSHA Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

TSHA Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Taysha Gene Therapies Analyst EPS Estimates

Current Year EPS Consensus Estimate:($0.39) EPS
Next Year EPS Consensus Estimate: ($0.46) EPS

TSHA Earnings Date and Information

Taysha Gene Therapies last issued its earnings data on March 19th, 2024. The reported $0.35 EPS for the quarter. The firm earned $3.60 million during the quarter, compared to analyst estimates of $4.75 million. Taysha Gene Therapies has generated ($0.67) earnings per share over the last year (($0.67) diluted earnings per share). Earnings for Taysha Gene Therapies are expected to decrease in the coming year, from ($0.39) to ($0.46) per share. Taysha Gene Therapies has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 9th, 2024 based off prior year's report dates.

Taysha Gene Therapies Earnings History by Quarter

Export to Excel
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
5/9/2024
Estimated)		------- 
3/19/2024Q4 2023-$0.35+$0.35($0.22)$4.75 million$3.60 million
11/14/2023Q3 2023($0.13)($0.13)-$0.67$2.65 million$4.75 million
8/14/2023Q2 2023($0.31)($0.38)($0.07)($0.38)$2.00 million$2.40 million
5/11/2023Q1 2023($0.39)($0.28)+$0.11($0.28)-$4.71 million
3/28/2023Q4 2022($0.41)($0.99)($0.58)($0.99)-$2.50 million
11/8/2022Q3 2022($0.89)($0.64)+$0.25($0.64)--
8/11/2022Q2 2022($1.05)($0.84)+$0.21($0.84)--
5/16/2022Q1 2022($1.04)($1.31)($0.27)($1.31)--    
3/31/2022Q4 2021($1.21)($1.32)($0.11)($1.32)--    
11/10/2021Q3 2021($1.02)($1.35)($0.33)($1.35)--    
8/16/2021Q2 2021($0.84)($1.09)($0.25)($1.09)--    
5/11/2021Q1 2021($0.54)($0.87)($0.33)($0.87)--  

Taysha Gene Therapies Earnings - Frequently Asked Questions

When is Taysha Gene Therapies's earnings date?

Taysha Gene Therapies has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 9th, 2024 based off last year's report dates. Learn more on TSHA's earnings history.

How much revenue does Taysha Gene Therapies generate each year?

Taysha Gene Therapies (NASDAQ:TSHA) has a recorded annual revenue of $15.45 million.

How much profit does Taysha Gene Therapies generate each year?

Taysha Gene Therapies (NASDAQ:TSHA) has a recorded net income of -$111.57 million. TSHA has generated -$0.67 earnings per share over the last four quarters.

What is Taysha Gene Therapies's EPS forecast for next year?

Taysha Gene Therapies's earnings are expected to decrease from ($0.39) per share to ($0.46) per share in the next year.


More Earnings Resources from MarketBeat

Related Companies:
Earnings Tools:
Earnings By Country:
Latest Articles:
This page (NASDAQ:TSHA) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
The “Perfect Storm” for Gold
Gold Safe Exchange
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
Biden’s $374B Giveaway Into This Sector
DTI
The #1 Crypto for 2024
InvestorPlace
He Is Giving Away Bitcoin
Crypto Swap Profits
Urgent alert: open this for a huge profit potential
Timothy Sykes
Top 5 AI Stocks to Buy for 2024
Market Moving Trends